P2Y12 inhibitor monotherapy combined with colchicine following PCI in ACS patients: the MACT pilot study

Seung-Yul Lee; Young-Hoon Jeong; Kyeong  Ho Yun; Jae  Young Cho; Diana Gorog; Dominick J. Angiolillo; Kim Jin Won; Yangsoo  Jang

P2Y12 inhibitor monotherapy combined with colchicine following PCI in ACS patients: the MACT pilot study

Seung-Yul Lee, Young-Hoon Jeong, Kyeong Ho Yun, Jae Young Cho, Diana Gorog, Dominick J. Angiolillo, Kim Jin Won, Yangsoo Jang

Research output: Contribution to journal › Article › peer-review

Abstract

This proof-of-concept pilot trial investigated the feasibility of ticagrelor or prasugrel P2Y12 inhibitor monotherapy combined with colchicine immediately after PCI in ACS patients. The day after PCI, aspirin was replaced with low-dose colchicine (0.6 mg daily) on ticagrelor or prasugrel maintenance. Among 200 ACS patients enrolled, stent thrombosis occurred in two patients for 3 months. High platelet reactivity assessed by VerifyNow assay was low at discharge and hs-CRP levels decreased significantly within 1 month after PCI. Accordingly, P2Y12 inhibitor mono antiplatelet and colchicine therapy is feasible in ACS patients undergoing PCI and associated with favorable platelet function and inflammatory profiles.

Original language	English
Journal	JACC: Cardiovascular Interventions
Publication status	Accepted/In press - 17 May 2023

Embargoed Document

Manuscript_R2_Clean
Accepted author manuscript, 1.74 MB

Cite this

@article{05d55f616fb94db79ed87c5efe4e865f,

title = "P2Y12 inhibitor monotherapy combined with colchicine following PCI in ACS patients: the MACT pilot study",

abstract = "This proof-of-concept pilot trial investigated the feasibility of ticagrelor or prasugrel P2Y12 inhibitor monotherapy combined with colchicine immediately after PCI in ACS patients. The day after PCI, aspirin was replaced with low-dose colchicine (0.6 mg daily) on ticagrelor or prasugrel maintenance. Among 200 ACS patients enrolled, stent thrombosis occurred in two patients for 3 months. High platelet reactivity assessed by VerifyNow assay was low at discharge and hs-CRP levels decreased significantly within 1 month after PCI. Accordingly, P2Y12 inhibitor mono antiplatelet and colchicine therapy is feasible in ACS patients undergoing PCI and associated with favorable platelet function and inflammatory profiles.",

author = "Seung-Yul Lee and Young-Hoon Jeong and {Ho Yun}, Kyeong and {Young Cho}, Jae and Diana Gorog and Angiolillo, {Dominick J.} and {Jin Won}, Kim and Yangsoo Jang",

year = "2023",

month = may,

day = "17",

language = "English",

journal = "JACC: Cardiovascular Interventions",

}

TY - JOUR

T1 - P2Y12 inhibitor monotherapy combined with colchicine following PCI in ACS patients: the MACT pilot study

AU - Lee, Seung-Yul

AU - Jeong, Young-Hoon

AU - Ho Yun, Kyeong

AU - Young Cho, Jae

AU - Gorog, Diana

AU - Angiolillo, Dominick J.

AU - Jin Won, Kim

AU - Jang, Yangsoo

PY - 2023/5/17

Y1 - 2023/5/17

N2 - This proof-of-concept pilot trial investigated the feasibility of ticagrelor or prasugrel P2Y12 inhibitor monotherapy combined with colchicine immediately after PCI in ACS patients. The day after PCI, aspirin was replaced with low-dose colchicine (0.6 mg daily) on ticagrelor or prasugrel maintenance. Among 200 ACS patients enrolled, stent thrombosis occurred in two patients for 3 months. High platelet reactivity assessed by VerifyNow assay was low at discharge and hs-CRP levels decreased significantly within 1 month after PCI. Accordingly, P2Y12 inhibitor mono antiplatelet and colchicine therapy is feasible in ACS patients undergoing PCI and associated with favorable platelet function and inflammatory profiles.

AB - This proof-of-concept pilot trial investigated the feasibility of ticagrelor or prasugrel P2Y12 inhibitor monotherapy combined with colchicine immediately after PCI in ACS patients. The day after PCI, aspirin was replaced with low-dose colchicine (0.6 mg daily) on ticagrelor or prasugrel maintenance. Among 200 ACS patients enrolled, stent thrombosis occurred in two patients for 3 months. High platelet reactivity assessed by VerifyNow assay was low at discharge and hs-CRP levels decreased significantly within 1 month after PCI. Accordingly, P2Y12 inhibitor mono antiplatelet and colchicine therapy is feasible in ACS patients undergoing PCI and associated with favorable platelet function and inflammatory profiles.

M3 - Article

JO - JACC: Cardiovascular Interventions

JF - JACC: Cardiovascular Interventions

ER -

P2Y12 inhibitor monotherapy combined with colchicine following PCI in ACS patients: the MACT pilot study

Abstract

Embargoed Document

Fingerprint

Cite this